Physicians' Academy for Cardiovascular Education

Kidney disease & CVD

Follow the news, literature, and elearning on new developments in the management of Kidney disease and CVD

Primary care as gatekeeper in CKD and the need for collaboration with nephrologists

10' education - July 13, 2022 - Prof. Kamlesh Khunti, MD, PhD

Discussion - Rethinking the role of nephrologists in prevention of CKD - The opportunity of early risk identification

10' education - July 6, 2022 - Prof. Christoph Wanner, MD, Rikke Borg, MD, PhD, and prof. Kamlesh Khunti, MD, PhD

Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD

Why is early screening and risk identification of CKD in diabetes important?

10' education - July 6, 2022 - Rikke Borg, MD, PhD

Barriers for preventing CKD in patients with diabetes

10' education - June 28, 2022 - Prof. Christoph Wanner, MD

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD

Cardiorenal effects of nonsteroidal MRAs in patients with CKD and T2DM

10' education - June 7, 2022 - Eugene E. Wright, Jr., MD, Jolanta Małyszko, MD, PhD and María José Soler, MD, PhD

New insights and guidelines for the management of CKD and diabetes

10' education - May 31, 2022 - Prof. Johannes Mann, MD

Which patients benefit from potassium binders?

10' education - Feb. 15, 2022 - Kevin Damman, MD, PhD

Role of a non-steroidal MRA in the treatment spectrum of patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Interpreting findings of studies on a non-steroidal MRA in T2DM and CKD

10' education - Nov. 9, 2021 - Prof. George Bakris, MD, prof. Betram Pitt, MD and prof. Rajiv Agarwal, MD

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

Dialogue on how to overcome clinical inertia with regard to SGLT2i

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME

Introduction on tackling cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

E-learning Rethinking the role of nephrologists in prevention of CKD – The opportunity of early risk identification

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

In this series, three presenters discuss the importance of early screening and the need for a multidisciplinary approach to identify patients at risk for CKD. Watch the presentations and answer the questions in the tests!

SGLT2i attenuates longitudinal rises in CV biomarkers in T2DM patients

Literature - July 25, 2022 - Vaduganathan M, et al. - J Am Coll Cardiol. 2022

The CANVAS biomarker substudy showed that canagliflozin delays the expected increase in CV biomarkers in T2DM patients. It also reduces the risk of HF and renal disease events irrespective of biomarker levels at baseline.

E-learning Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Three speakers present the KDIGO guidelines, evidence of studies with GLP-1RAs and kidney outcomes and tell us what we can expect in the near future with regard to GLP-1RAs in nephrology.

Primary care as gatekeeper in CKD and the need for collaboration with nephrologists

10' education - July 13, 2022 - Prof. Kamlesh Khunti, MD, PhD

"We really need to think about a collaborative, integrated approach, where primary care and specialists are working together to manage CKD", says Prof. Khunti.

Discussion - Rethinking the role of nephrologists in prevention of CKD - The opportunity of early risk identification

10' education - July 6, 2022 - Prof. Christoph Wanner, MD, Rikke Borg, MD, PhD, and prof. Kamlesh Khunti, MD, PhD
Watch a discussion by three experts on the importance of early screening and the need for a multidisciplinary approach to identify patients at risk for CKD.

Watch a discussion by three experts on the importance of early screening and the need for a multidisciplinary approach to identify patients at risk for CKD.

Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD
Watch a discussion by three experts on the role of GLP-1RA in preventing CKD in patients with diabetes.

Watch a discussion by three experts on the role of GLP-1RA in preventing CKD in patients with diabetes.

Why is early screening and risk identification of CKD in diabetes important?

10' education - July 6, 2022 - Rikke Borg, MD, PhD
Rikke Borg gives an overview on CKD in patients with diabetes with a focus on how to screen for early signs of CKD.

Rikke Borg gives an overview on CKD in patients with diabetes with a focus on how to screen for early signs of CKD.

No need to stop SGLT2i therapy when early eGFR decrease occurs in HFrEF patients

Literature - July 5, 2022 - Zannad F, et al. - Eur J Heart Fail. 2022

At the beginning of empagliflozin treatment, a mild eGFR decrease is to be expected. However, this does not deprive patients with HFrEF from benefiting from SGLT2i therapy, according to a secondary analysis of the EMPEROR-Reduced trial.

Barriers for preventing CKD in patients with diabetes

10' education - June 28, 2022 - Prof. Christoph Wanner, MD
Prof. Wanner gives an introduction on improving early identification of CKD and changing the eGFR slope of patients with diabetes by working together with other healthcare professionals.

Prof. Wanner gives an introduction on improving early identification of CKD and changing the eGFR slope of patients with diabetes by working together with other healthcare professionals.

Updates to the Standards of Medical Care in Diabetes 2022 by ADA

News - June 21, 2022

The American Diabetes Association (ADA) has made important updates to the Standard of Medical Care in Diabetes 2022. Updates include new data on finerenone in T2DM and CKD, SGLT2i in T2DM and calculating eGFR.

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD
In this video, Prof. Tuttle discusses GLP-1RAs for CVD risk reduction and preservation of kidney function in CKD. Moreover, she talks about multidisciplinary team care for patients with T2DM and CKD.

In this video, Prof. Tuttle discusses GLP-1RAs for CVD risk reduction and preservation of kidney function in CKD. Moreover, she talks about multidisciplinary team care for patients with T2DM and CKD.

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD
GLP-1RAs may result in beneficial effects on renal outcomes, as shown by analyses of secondary endpoints in large trials. What are the potential mechanisms leading to CVD and CKD risk reduction?

GLP-1RAs may result in beneficial effects on renal outcomes, as shown by analyses of secondary endpoints in large trials. What are the potential mechanisms leading to CVD and CKD risk reduction?